Eisai at a glance
Our History - A glance into the history of Eisai
1941 |
Eisai founded in Japan |
2001 |
First Environmental and Social Report published |
1961 |
Eisai listed on the Tokyo/Osaka stock exchange |
2004 |
European Regional HQ established (London) |
1970 |
Eisai establishes commercial operations in Indonesia |
2005 |
Eisai started marketing Zonegran® (zonisamide) in the US, for the adjunctive treatment of partial-onset seizures in adults |
1981 |
Eisai establishes its North American operation in California |
2006 |
Plans announced for a Strategic European Base in UK |
1988 |
European operations established |
2007 |
Prialt® (ziconotide), for the treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia, launched in Europe
Inovelon® (rufinamide) is first launched in Germany, for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) |
1990 |
Eisai establishes its UK R&D operation, Eisai London Research Laboratories, at University College London |
2008 |
First Eisai launch of NeuroBloc® (botulinum toxin type B) for cervical dystonia in the UK and Germany
|
1993 |
Eisai introduces the corporate philosophy of hhc (human health care) |
2009 |
European Knowledge Centre opens in Hatfield, UK as hub of European operations |
1996 |
Commercial operations start in France and Germany |
2010 |
Eisai launches 'aboutmemoryproblems.com' website designed to help people recognise the early signs of Alzheimer's disease and provide guidance for seeking help and advice for those who are concerned about someone close to them
Zebinix® (eslicarbazepine acetate) launched in Sweden for the adjunctive treatment of partial-onset seizures in adults
Eisai submits regulatory applications for investigational anticancer agent eribulin mesylate (E7389) in Japan, the United States and Europe
Eisai subsidiary launched in Canada |
1997 |
Aricept® (donepezil hydrochloride), for the treatment of Alzheimer’s disease, first launched (USA) |
2014 |
Eisai opens its first office in Melbourne, Australia. |